Session Title: Vasculitis - Poster II: ANCA-Associated Vasculitis
Session Type: ACR Poster Session B
Session Time: 9:00AM-11:00AM
Background/Purpose: Ocular involvement in ANCA-associated vasculitis (AAV) can cause substantial morbidity. We aimed to characterize patterns of ocular involvement in AAV and their response to treatment.
Methods: We analyzed data from two large randomized controlled trials of AAV – the Rituximab in ANCA-Associated Vasculitis (RAVE) trial and Wegener’s Granulomatosis Etanercept Trial (WGET). Ocular involvement was assessed at baseline and patients were followed until the common close-out dates. Pooled post-hoc analysis was performed of initial and overall prevalences of ocular involvement. Clinical features associated with ocular involvement, time to remission, and relapse were assessed by Cox proportional hazards and logistic regression models.
Results: 377 patients were included (Table 1). 64 patients (17.0%) had ocular involvement at study entry; conjunctivitis/episcleritis was the most common subtype, while uveitis and retinal involvement were the rarest (Table 2). Over a median follow-up time of 35.4 months, 24 patients (6.4%) developed new ocular involvement. Non-white race was associated with higher odds of having retroorbital mass/proptosis (OR 4.51; P = 0.014). Female sex (OR 2.70; P = 0.032) and PR3 ANCA positive status (OR 4.48; P = 0.048) were associated with higher odds of having scleritis. Among patients with ocular disease at study entry, median times to remission were 1.3 months for conjunctivitis/episcleritis, 1.4 months for retroorbital mass/proptosis, 0.2 months for scleritis, and 0.3 months for retinal exudates/hemorrhage. Treatment with rituximab trended toward association with decreased time to remission of retroorbital mass/proptosis (HR 10.0; P = 0.060). Relapses of ocular disease occurred in 5 patients (12.5%) with conjunctivitis/episcleritis, 3 patients (25.0%) with retroorbital mass/proptosis, and 6 patients (37.5%) with scleritis. No patient treated with rituximab developed a relapse of conjunctivitis/episcleritis or proptosis.
Conclusion: Conjunctivitis/episcleritis, scleritis, and retroorbital mass/proptosis were the most common ocular manifestations of AAV. Race and sex may be associated with certain subtypes of ocular involvement. The relative efficacies of cyclophosphamide and rituximab in the treatment of retroorbital mass/proptosis deserve further study.
|Age (years), mean (SD)||51.4 (15.5)|
|Sex, male, n (%)||208 (55.2)|
|Race, white, n (%)||350 (92.8)|
|New diagnosis, n (%)||176 (46.7)|
|Limited disease, n (%)||52 (13.8)|
|WG diagnosis, n (%)||327 (87.0)|
|PR3 ANCA positive, n (%)||277 (74.5)|
|MPO ANCA positive, n (%)||70 (18.8)|
|RAVE trial participant, n (%)||197 (52.3)|
|Treatment with rituximab, n (%)||99 (26.3)|
|WGET trial participant, n (%)||180 (47.7)|
|Treatment with etanercept, n (%)||89 (23.6)|
|Baseline prevalence||Overall prevalence|
|Conjunctivitis/episcleritis, n (%)||41 (10.9)||62 (16.4)|
|Retroorbital mass/proptosis, n (%)||12 (3.2)||17 (4.5)|
|Uveitis, n (%)||0 (0.0)||2 (0.5)|
|Scleritis, n (%)||16 (4.2)||22 (5.8)|
|Retinal exudates/hemorrhage, n (%)||1 (0.3)||1 (0.3)|
References: 1. Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med. Jan 27 2005;352(4):351-361. 2. Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. Aug 1 2013;369(5):417-427.
To cite this abstract in AMA style:Cai S, Papaliodis G, Lu L, Choi HK, Specks U, Merkel PA, Seo P, Spiera RF, Langford CA, Hoffman GS, Kallenberg CGM, St Clair W, Tchao N, Fervenza F, Monach PA, McCune WJ, Stone JH, Miloslavsky E. Ocular Manifestations of ANCA-Associated Vasculitis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/ocular-manifestations-of-anca-associated-vasculitis/. Accessed July 23, 2019.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/ocular-manifestations-of-anca-associated-vasculitis/